

Efficient tumour formation by single human melanoma cells

Elsa Quintana^{1*}, Mark Shackleton^{1*}, Michael S. Sabel², Douglas R. Fullen³, Timothy M. Johnson⁴ & Sean J. Morrison¹

A fundamental question in cancer biology is whether cells with tumorigenic potential are common or rare within human cancers. Studies on diverse cancers, including melanoma, have indicated that only rare human cancer cells (0.1–0.0001%) form tumours when transplanted into non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice. However, the extent to which NOD/SCID mice underestimate the frequency of tumorigenic human cancer cells has been uncertain. Here we show that modified xenotransplantation assay conditions, including the use of more highly immunocompromised NOD/SCID interleukin-2 receptor gamma chain null (*Il2rg*^{-/-}) mice, can increase the detection of tumorigenic melanoma cells by several orders of magnitude. In limiting dilution assays, approximately 25% of unselected melanoma cells from 12 different patients, including cells from primary and metastatic melanomas obtained directly from patients, formed tumours under these more permissive conditions. In single-cell transplants, an average of 27% of unselected melanoma cells from four different patients formed tumours. Modifications to xenotransplantation assays can therefore dramatically increase the detectable frequency of tumorigenic cells, demonstrating that they are common in some human cancers.

Traditionally, many cancer cells have been considered to have tumorigenic potential, even though no assay has yet demonstrated that a high percentage of single human cancer cells can form tumours. In contrast, the cancer stem-cell model has suggested that only small subpopulations of cancer cells have tumorigenic potential, based on experiments in which human cancer cells were xenotransplanted into NOD/SCID mice. For example, only one in a million (0.0001%) human melanoma cells is tumorigenic in NOD/SCID mice¹. Indeed, most human cancers have only rare (<0.1%) tumorigenic/leukaemogenic cells (also called cancer-initiating cells or cancer stem cells) when transplanted into NOD/SCID or other highly immunocompromised mice^{1–11}. Nonetheless, recent studies of mouse haematopoietic malignancies have raised the question of whether NOD/SCID assays underestimate the frequency of human cancer-initiating cells^{12–14}. Indeed, human leukaemias exhibit a modestly higher frequency of leukaemogenic cells when assayed in mice that are more highly immunocompromised than NOD/SCID mice^{15,16}, although leukaemogenic cells still represent only 1% of cells in one such model¹⁷. The critical question is whether optimization of xenotransplantation assays could reveal that some human cancers actually have very common cells with tumorigenic potential despite only having rare tumorigenic cells in NOD/SCID mice.

The question of whether cells with tumorigenic potential are common or rare within human cancers has fundamental implications for therapy. If tumorigenic cells represent small minority populations, as suggested by the evidence supporting the cancer stem-cell model, improved anti-cancer therapies may be identified based on the ability to kill these cancer stem cells rather than the bulk population of non-tumorigenic cancer cells^{18,19}. Alternatively, if cells with tumorigenic potential are common, it will not be possible to treat cancer more effectively or to understand cancer biology better by focusing on small minority subpopulations.

Melanoma-initiating cells are rare in NOD/SCID mice

Melanoma-initiating (tumorigenic) cells were reported to be rare based on the observation that only 1 in 1,090,000 human metastatic

melanoma cells formed tumours within 8 weeks of transplantation into NOD/SCID mice¹. To assess this, we transplanted 10²–10⁷ freshly dissociated melanoma cells obtained directly from seven patients subcutaneously into NOD/SCID mice (see Supplementary Table 1 for more information on tumours). Palpable tumours were evident in some mice 8 weeks after injection of cells from four of seven melanomas (Fig. 1A, B). Limiting dilution analysis²⁰ indicated that the average frequency of cells that formed tumours within 8 weeks of transplantation into NOD/SCID mice was 1 in 837,000 (Fig. 1C), confirming the published estimate¹. However, most tumours took more than 8 weeks to develop (Fig. 1A). On average, tumours first became palpable after 11.4 ± 3.8 weeks (mean ± s.d.), or 14.3 ± 7.6 weeks for tumours that arose from fewer than 10,000 injected cells. Variability was high, but the average frequency of cells that formed tumours within 32 weeks was 1 in 111,000 (Fig. 1C; *P* < 0.0001). The frequency of melanoma-initiating cells is therefore significantly underestimated when tumour formation is monitored for only 8 weeks.

Modified assay reveals more tumorigenic cells

Some normal human haematopoietic cells engraft more efficiently in NOD/SCID mice lacking the interleukin-2 gamma receptor (NOD/SCID *Il2rg*^{-/-}) compared with NOD/SCID mice, owing in part to the lack of natural-killer cell activity in NOD/SCID *Il2rg*^{-/-} mice^{21–24}. NOD/SCID *Il2rg*^{-/-} mice have also been used to study cancer arising from human cell lines^{25,26} or human leukaemias^{15,27}. We thus compared human melanoma growth in NOD/SCID mice and NOD/SCID *Il2rg*^{-/-} mice to test whether more tumorigenic cells could be detected in more highly immunocompromised NOD/SCID *Il2rg*^{-/-} mice. Xenografted melanoma cells (human melanomas grown in NOD/SCID mice) from five patients were dissociated, then live human cells were isolated by flow cytometry (excluding mouse haematopoietic and endothelial cells; Fig. 2a) and transplanted side-by-side into NOD/SCID *Il2rg*^{-/-} and NOD/SCID mice (Fig. 2b). Tumours grew faster in NOD/SCID *Il2rg*^{-/-} mice (Fig. 2b and

¹Howard Hughes Medical Institute, Life Sciences Institute, Department of Internal Medicine, and Center for Stem Cell Biology, University of Michigan, Ann Arbor, Michigan 48109-2216, USA. ²Department of Surgery, ³Department of Pathology, and ⁴Department of Dermatology, University of Michigan, Ann Arbor, Michigan 48109, USA.

*These authors contributed equally to this work.




Figure 1 | Only rare human melanoma cells form tumours in NOD/SCID mice. **A**, Tumour development after subcutaneous injection of unfractured primary melanoma cells directly from seven patients into NOD/SCID mice. Dots represent the times after injection at which individual tumours were first palpable and are coloured according to cell dose. Crosses are injections that failed to form tumours. Dotted line indicates 8 weeks after injection. **B**, All tumours were diagnosed as metastatic melanoma by clinical pathology (see Supplementary Table 1 for more information). The tumours that formed in mice (**a**, arrow) became large, grew quickly once they were palpable and were histologically similar to the patient tumours from which they were derived. Flow cytometry demonstrated that most tumour cells expressed human HLA (**b**; dotted line represents unstained control). Some tumours were highly pigmented (**c**) whereas others contained variable pigmentation (**d**) or were amelanotic (scale bar, 1 cm). Sections stained with haematoxylin and eosin through the same tumours showed pigmented cells (**e**, **f**, see arrows; bars, 25 μ m). Cytospun cells contained melanin, as indicated by Fontana-Masson staining (**g**, **h**, arrows; bars, 25 μ m), and showed widespread S100 β staining (**i**, **j**), a marker used to diagnose melanoma⁴⁰. **C**, Limiting dilution analyses of the frequency of tumorigenic melanoma cells in Fig. 1A at 8 weeks or 32 weeks after transplantation (* $P < 0.0001$).

Supplementary Fig. 1), and an increased ($P < 0.05$) frequency of melanoma-initiating cells was observed in NOD/SCID *Il2rg*^{-/-} mice compared with NOD/SCID mice in every tumour tested (Supplementary Fig. 2). Two melanoma specimens obtained directly from patients (465 and 481) also exhibited a significantly ($P < 0.05$) higher frequency of melanoma-initiating cells in NOD/SCID *Il2rg*^{-/-} mice (Supplementary Fig. 2).

To test whether NOD/SCID *Il2rg*^{-/-} mice selected for growth of more aggressive clones, we transplanted cells from tumours grown in NOD/SCID *Il2rg*^{-/-} mice back into NOD/SCID versus NOD/SCID *Il2rg*^{-/-} recipients. The frequency of detectable tumorigenic cells in these tumours went back down in NOD/SCID mice (Supplementary Fig. 3a), demonstrating that heritable changes in the frequency of melanoma-initiating cells did not occur as a result of having grown in NOD/SCID *Il2rg*^{-/-} mice. An increased xenogeneic immune response probably contributes to reduced tumorigenesis by melanoma cells in NOD/SCID mice compared with NOD/SCID *Il2rg*^{-/-} mice.

We next tested whether further improvements could be made in melanoma cell engraftment. Co-injection with Matrigel²⁸ increases tumour formation by cancer cell lines^{29,30} and enhances the engraftment of primary human epithelial cancer cells in immunocompromised mice^{6,31}. To test the effect of Matrigel on the ability to detect tumorigenic melanoma cells, we isolated live human melanoma cells by flow cytometry (Fig. 2a) from xenografts derived from three patients. The same cell preparations were transplanted into NOD/SCID *Il2rg*^{-/-} mice after mixing with either vehicle (see Methods) or vehicle with Matrigel. Tumour cells injected with Matrigel produced tumours that grew faster than cells injected with vehicle alone (Fig. 2c and Supplementary Fig. 4a), and limiting dilution analysis revealed that in every case more melanoma cells were tumorigenic in Matrigel (Supplementary Fig. 4b).

To quantify the combined effect of the individual assay improvements described above, we performed side-by-side transplantation of live melanoma cells isolated by flow cytometry from xenografted tumours from three different patients. The same cell preparations were either mixed with vehicle and injected into NOD/SCID mice or mixed with Matrigel and injected into NOD/SCID *Il2rg*^{-/-} mice. In every case, we observed much higher frequencies of tumorigenic cells in the NOD/SCID *Il2rg*^{-/-} mice. On average, more than 5,000-fold more cells exhibited tumorigenic activity under the modified assay conditions, in which an average of 1 in 9 human melanoma cells formed tumours (Fig. 2d). These results indicate that xenotransplantation assays can be modified to detect much higher than expected frequencies of human cells with tumorigenic potential.

Tumorigenic potential is common in melanoma

To ensure that our modified assay conditions did not somehow confer tumorigenic capacity on normal human cells, we injected 10,000 primary human melanocytes and/or 100,000 primary human mesenchymal stem cells with Matrigel into NOD/SCID *Il2rg*^{-/-} mice. These injections did not lead to the formation of tumours (Fig. 3a). The frequency of tumorigenic melanoma cells also did not increase with passaging in mice (Supplementary Fig. 4c). Therefore, this xenotransplantation assay does not confer tumorigenic potential on human cells. Consistent with this, serial transplantation experiments demonstrated that the increased tumorigenicity of melanoma cells in NOD/SCID *Il2rg*^{-/-} mice did not reflect a heritable change in the transplanted cells themselves (Supplementary Fig. 3a).

To determine whether xenografted melanomas consistently exhibit high frequencies of tumorigenic cells, we tested five additional tumour samples in an independent series of experiments, including some tumours that exhibited rare tumorigenic cells in NOD/SCID mice (Fig. 1). In each case, live human melanoma cells were isolated by flow cytometry (Fig. 2a) and injected with Matrigel into NOD/SCID *Il2rg*^{-/-} mice. Palpable tumours from the injection of eight cells were first detected 10 \pm 2 weeks after injection. Every tumour exhibited a high frequency of tumorigenic cells (range 1 in 21 to 1 in 5 cells), averaging 1 in 9 cells (Fig. 3b).

To assess whether melanoma cells obtained directly from patients also contain a high frequency of cells with tumorigenic potential, we assessed cells obtained from six patients. These included four metastatic melanomas and two primary cutaneous melanomas. Live melanoma cells were isolated by flow cytometry, excluding human haematopoietic (CD45⁺ or glycophorinA⁺) and endothelial cells (CD31⁺), which collectively represented 50 \pm 33% of cells in tumours obtained directly from patients. These excluded cells were confirmed to be haematopoietic and endothelial cells rather than melanoma cells by microscopy, and were greatly depleted of tumorigenic activity when transplanted (data not shown). The melanoma cells isolated by flow cytometry were mixed with Matrigel and injected into NOD/SCID *Il2rg*^{-/-} mice. On average, palpable tumours from the injection of 10 cells were first detected 13 \pm 4 weeks after injection. Every tumour exhibited a high frequency of




Figure 2 | Modifications to the xenotransplantation assay reveal that many more human melanoma cells have tumorigenic potential than detected in NOD/SCID mice.

a, Live human melanoma cells were isolated from xenografted tumours by flow cytometry. After gating to eliminate debris and dead cells, additional gates were drawn to select human HLA⁺ cells and to exclude mouse haematopoietic (CD45 and TER119) and endothelial (CD31) cells (middle panel). The human HLA⁺ cells consistently formed tumours upon transplantation into immunocompromised mice whereas mouse haematopoietic and endothelial cells did not (data not shown). **b**, Tumour development after side-by-side subcutaneous injections of 4,000 human melanoma cells from a xenograft derived from patient 308 into NOD/SCID or NOD/SCID *Il2rg*^{-/-} mice. **c**, Tumour development after side-by-side injections of 400 human melanoma cells from a xenograft derived from patient 205 cells into NOD/SCID *Il2rg*^{-/-} mice, with or without Matrigel. Photographs in **b** and **c** show resulting tumours at the time of analysis (bars, 1 cm). Similar experiments conducted with xenografted and non-xenografted tumours from several patients demonstrated that a significantly higher frequency of human melanoma cells formed tumours when injected into NOD/SCID *Il2rg*^{-/-} mice (Supplementary Fig. 2) or with Matrigel (Supplementary Fig. 4b). The tumours were also palpable earlier and grew faster (Supplementary Figs 1 and 4a). **d**, Limiting dilution analyses of tumours that arose after 8 weeks in NOD/SCID or NOD/SCID *Il2rg*^{-/-} mice from the side-by-side transplantation of melanoma cells (derived from xenografts) mixed with vehicle or Matrigel, respectively. In all cases, melanoma-initiating cells were significantly (**P* < 0.05) more frequent in the modified assay and represented 1 in 5 to 1 in 15 cells.

tumorigenic cells, with an average of 1 in 4 injected cells forming a tumour based on limiting dilution analysis (Fig. 3c). In tumours obtained directly from patients 492, 501 and 509 (the last a cutaneous primary tumour), every injection (6/6) of only 10 cells produced a tumour (Fig. 3c).

We have thus performed injections of small numbers of melanoma cells from 12 different patients and have not yet found a tumour that contained rare tumorigenic cells. Tumorigenic cells were common in all tumours, irrespective of whether they were derived from xenografts or directly from patients, and whether they were from primary cutaneous or metastatic melanomas.

Tumorigenesis by single, unselected melanoma cells

To our knowledge, no study has yet demonstrated that a high percentage of single cells from a spontaneously occurring human cancer has the potential to form tumours *in vivo*. To assess this, we sorted live human melanoma cells by flow cytometry from xenografted tumours obtained from four different patients, then deposited one cell per well in Terasaki plates (well volume 10 μ l). Wells were visually confirmed to contain a single cell, then mixed with Matrigel and injected into NOD/SCID *Il2rg*^{-/-} mice (Fig. 4a). Depending on

the patient, 12–65% of single cells formed tumours (Fig. 4b). Overall, 69 tumours (27%) developed from 254 single-cell injections. This demonstrates that xenotransplantation assays can be improved to the point where single human melanoma cells can engraft and form tumours *in vivo*, confirming that cells with tumorigenic potential are common within human melanomas.

Additional modifications to xenotransplantation assays may further improve the detection of human cells able to form tumours, such that 25% could remain an underestimate of the percentage of melanoma cells with tumorigenic potential. Because some melanoma cells are fated to undergo cell death or senescence as a result of deleterious genetic changes or proximity to necrotic areas, it is possible that most melanoma cells that are not fated to undergo cell death or senescence have tumorigenic potential. It also remains possible that some melanomas, particularly early-stage primary tumours, may contain less frequent tumorigenic cells than observed in our studies.

Tumorigenic cells are phenotypically heterogeneous

To assess whether tumorigenic melanoma cells are phenotypically distinct from melanoma cells that fail to form tumours, we examined the expression of more than 50 surface markers on melanomas

a

Injection of normal human cells co-mixed with Matrigel in NOD/SCID <i>Il2rg</i> ^{-/-} mice	Number of tumours/ number of injections
10,000 primary melanocytes	0/6
100,000 mesenchymal stem cells	0/6
10,000 melanocytes + 100,000 mesenchymal stem cells	0/6

b

Tumour origin	Patient	Number of tumours/ number of infections			Melanoma-initiating cell frequency (95% confidence interval)	Weeks to first palpability
		Cells per injection				
		200	40	8		
Xenografts	193	12/12	12/12	8/12	1/7 (1/4–1/14)	11 ± 1
	205	18/18	18/18	13/18	1/6 (1/3–1/11)	9 ± 2
	214	6/6	5/6	2/6	1/21 (1/9–1/48)	9 ± 0
	308	11/11	11/12	10/11	1/8 (1/4–1/15)	8 ± 2
	405	6/6	5/6	4/6	1/14 (1/6–1/33)	9 ± 1
	481	6/6	6/6	5/6	1/5 (1/2–1/12)	11 ± 0
	All	59/59	57/60	42/59	1/9 (1/7–1/12)	10 ± 2

c

Tumour origin	Patient	Number of tumours/ number of infections			Melanoma-initiating cell frequency (95% confidence interval)	Weeks to first palpability
		Cells per injection				
		1,000	100	10		
Direct from patients	487	6/6	6/6	5/6	1/6 (1/2–1/15)	12 ± 3
	491	6/6	6/6	5/6	1/6 (1/2–1/15)	12 ± 3
	492	6/6	6/6	6/6	>1/11	9 ± 2
	501	6/6	6/6	6/6	>1/11	15 ± 2
	498 (cut)	6/6	6/6	5/6	1/6 (1/2–1/15)	20 ± 4
	509 (cut)	6/6	6/6	6/6	>1/11	10 ± 2
	All	36/36	36/36	33/36	1/4 (1/3–1/6)	13 ± 4

Figure 3 | A high percentage of human melanoma cells are tumorigenic, but normal human cells are not. **a**, Large doses of primary human melanocytes and/or mesenchymal stem cells were mixed with Matrigel and transplanted into NOD/SCID *Il2rg*^{-/-} mice. No tumours were palpable after 22 weeks. The frequency of melanoma-initiating cells in 12 human tumours obtained either from xenografts (**b**) or directly from patients (**c**) was calculated by limiting dilution analysis. Tumours from patients 498 and 509 were primary cutaneous lesions (cut), whereas other tumours were metastases (Supplementary Table 1). In each case, live human melanoma cells were isolated by flow cytometry, mixed in Matrigel and injected subcutaneously into NOD/SCID *Il2rg*^{-/-} mice. Eleven per cent of melanoma cells from xenografts and 25% of melanoma cells directly from patients formed tumours within 32 weeks of transplantation. Weeks to palpability (mean ± s.d.) are indicated for the lowest dose of cells from each tumour.

derived from several patients (Supplementary Table 2). These included markers of other cancer stem-cell populations, melanocytes, melanoma, neural-crest derivatives and other cell types. Fifteen of these markers (A2B5, c-kit, CD44, CD49B, CD49D, CD49f, CD54, CD133, CD166, E-cadherin, HNK-1, L1CAM, MCAM, N-cadherin and p75) were heterogeneously expressed by melanoma cells from multiple patients and were tested for the ability to distinguish tumorigenic from non-tumorigenic melanoma cells *in vivo* (Supplementary Table 2). In each case, melanoma cells were fractionated by flow cytometry (except CD133, which was sometimes fractionated using magnetic beads as in previous studies^{10,32}) and cells that expressed different levels of the indicated markers were injected into NOD/SCID *Il2rg*^{-/-} mice. In every case, tumours arose from all fractions of cells. We found no marker that distinguished tumorigenic from non-tumorigenic cells (Supplementary Table 2). Detailed results are shown for CD49f (α_6 integrin, a marker expressed by many different stem cells³³) and L1CAM (which is associated with CD133 expression in glioma stem cells³⁴) in Supplementary Fig. 5.

A previous study found that 1 in 120,735 (0.00083%) ABCB5⁺ metastatic melanoma cells formed tumours in NOD/SCID mice, a




Figure 4 | Efficient tumour development from the xenotransplantation of single human melanoma cells. **a**, Flow-cytometrically isolated human melanoma cells derived from xenografts from four patients were diluted into Terasaki microwells such that wells containing single cells could be identified by phase contrast microscopy. In control experiments, the presence of single cells was confirmed by the observation of single nuclei with Acridine Orange staining (inset) in 90 out of 90 cases. The single cells were mixed with Matrigel and injected into NOD/SCID *Il2rg*^{-/-} mice. Tumours arising from the injection of single cells were confirmed to be melanoma by haematoxylin and eosin, S100 and HMB45 staining (right panels show sections from a tumour that arose from a single cell obtained from patient 214). **b**, The percentage of single-cell injections (69/254 = 27%) that formed tumours within 20 weeks of transplantation. Weeks to first palpability (mean ± s.d.) are indicated for each set of tumours.

tenfold enrichment over unfractionated cells¹. Because ABCB5 expression has been shown to correlate with the expression of CD166 and CD133 (ref. 35), we tested whether CD166 or CD133 could enrich tumorigenic melanoma cells in the modified xenotransplantation assay (Supplementary Fig. 6). The frequency of CD133⁺ cells in tumours from 12 different patients was consistently lower (usually lower than 5%) than the frequency of tumorigenic cells in the same tumours (5–20%; Supplementary Fig. 6b). Moreover, CD133⁺ cells were not enriched for tumorigenic melanoma cells. Both CD133⁺ and CD133⁻ fractions from two different melanomas exhibited very high frequencies of tumorigenic cells (Supplementary Fig. 6c). Flow cytometry indicated that all of the resulting tumours contained both CD133⁺ and CD133⁻ cells, irrespective of whether they were derived from CD133⁺ or CD133⁻ cells (data not shown). Both CD166⁺ and CD166⁻ fractions also contained very high frequencies of tumorigenic melanoma cells (Supplementary Fig. 6f). We have therefore been unable to identify any phenotypic differences that distinguish tumorigenic from non-tumorigenic melanoma cells. These results raise the possibility that markers that enrich rare cells with tumorigenic potential in NOD/SCID mice may fail to distinguish tumorigenic from non-tumorigenic cells in assays that detect much higher frequencies of tumorigenic cells, though more work will be required to test this fully.

Discussion

Our data demonstrate that modifications in xenotransplantation assays can dramatically increase—by several orders of magnitude—the detectable frequency of cells with tumorigenic potential. This means that some cancers that appear to have rare tumorigenic cells in NOD/SCID mice actually have very common cells with tumorigenic capacity under other conditions. Other cancers may still have infrequent tumorigenic cells, even when studied under optimized conditions, but the frequency and phenotypic diversity of these cells

may be considerably greater than currently thought. Efforts to optimize the xenotransplantation of human cancer cells will be necessary to identify and study the full spectrum of human cancer cells capable of contributing to disease progression.

It is important to note that neither our study nor previous cancer stem-cell studies have addressed which cells actually contribute to tumour growth and disease progression in patients. These studies address the potential of cancer cells to proliferate extensively and to form tumours/leukaemias, not their actual fate within patients. Depending on how different the tumour environment is within patients compared with mouse models, it is possible that different cancer cells form tumours in mouse models than in human patients. Thus, although we observe a high percentage of melanoma cells that have the potential to proliferate extensively and form new tumours, it is possible that an even greater, or a much smaller, fraction of melanoma cells actually contributes to disease progression in patients.

Although most cancer stem-cell studies have detected only rare cells with tumorigenic capacity, it has recently been pointed out that leukaemogenic/tumorigenic cells do not necessarily have to be rare for cancers to follow a cancer stem-cell model¹⁷. Our observation that NOD/SCID xenotransplantation can dramatically underestimate the frequency of tumorigenic cells in at least some human cancers does not necessarily mean that such cancers will not have intrinsically different populations of tumorigenic and non-tumorigenic cells. Having said that, the frequency of tumorigenic cells in human melanoma is much higher than reported for any cancer previously suggested to follow a cancer stem-cell model, and we have not yet been able to identify phenotypic differences between melanoma cells that form tumours and those that do not. If markers that distinguish tumorigenic from non-tumorigenic melanoma cells in optimized xenotransplantation assays are identified in future, it will be important to test whether they reflect epigenetic differences between cells (as envisioned under the cancer stem-cell model) or genetic/environmental differences between cells.

Although cells with tumorigenic potential are likely to be much more frequent in most human cancers than estimated based on NOD/SCID transplantation, we believe the available evidence continues to support the conclusion that some human cancers follow a cancer stem-cell model. For example, data from the syngeneic transplantation of mouse acute myeloid leukaemia (AML)³⁶ and the transplantation of human AMLs into improved mouse models¹⁷ continue to suggest that many AMLs have small, intrinsically distinct subpopulations of AML-initiating cells. Extensive clinical experience with germ-cell cancers proves that therapies that eliminate the undifferentiated subset of cancer cells can cure patients, even if differentiated cancer cells are left behind^{37,38}. Nonetheless, careful optimization of xenotransplantation assays will probably yield a more nuanced view in which some cancers contain small subpopulations of cancer-initiating cells, whereas others contain common tumorigenic cells with little evidence of hierarchical organization. In both cases it will be critical to identify all cancer cells that have the potential to contribute to disease in patients in order to develop more effective therapies.

METHODS SUMMARY

Tumour cell preparation. Melanoma specimens were obtained from patients according to protocols approved by the Institutional Review Board of the University of Michigan Medical School (IRBMED approval numbers 2004-1058 and 2000-0713). Fresh tumour tissue was mechanically dissociated, enzymatically digested and filtered to obtain a single-cell suspension.

Cell labelling and sorting. Cells were stained with directly conjugated antibodies to human CD45, human CD31 and glycophorin A (to eliminate haematopoietic and endothelial cells from tumours obtained directly from patients) or mouse CD45, mouse CD31, Ter119 and human leukocyte antigen (HLA)-A, -B, -C (to eliminate mouse haematopoietic and endothelial cells and select human cells from xenografted tumours). Cells were resuspended in 10 µg ml⁻¹ 4,6-diamidino-2-phenylindole (DAPI) to label dead cells and sorted on FACSVantage SE or FACSAria flow cytometers. Some samples were labelled with anti-CD133 antibody and separated magnetically using a CD133 Cell Isolation

Kit (Miltenyi Biotec). When testing other markers, cells were usually labelled with unconjugated primary antibodies (see Supplementary Table 2) and then with directly conjugated secondary antibodies before staining with the directly conjugated antibodies described above.

Transplantation of human melanoma cells. After sorting, cells were counted and re-suspended in staining medium (L15 medium containing 1 mg ml⁻¹ BSA, 1% penicillin/streptomycin and 10 mM HEPES (pH7.4)), with or without 25% Matrigel (BD Biosciences). Subcutaneous injections of human melanoma cells were performed in NOD.CB17-Prkdcscid/J (NOD/SCID) and NOD.CB17-Prkdcscid Il2rgtm1Wjl/Szj (NOD/SCID *Il2rg*^{-/-}) mice (Jackson Laboratories) according to protocols approved by the Committee on the Use and Care of Animals at the University of Michigan (protocol number 9055).

Statistics. Limiting dilution analyses were performed based on Bonnefoix *et al.*³⁹, using the limdil function of the 'StatMod' package (author G.K. Smyth, <http://bioinf.wehi.edu.au/software/limdil/>), part of the R statistical software project (<http://www.r-project.org>). Melanoma-initiating cell frequencies were compared using likelihood ratio tests.

Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.

Received 21 August; accepted 14 October 2008.

- Schatton, T. *et al.* Identification of cells initiating human melanomas. *Nature* **451**, 345–349 (2008).
- Li, C. *et al.* Identification of pancreatic cancer stem cells. *Cancer Res.* **67**, 1030–1037 (2007).
- Prince, M. E. *et al.* Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. *Proc. Natl Acad. Sci. USA* **104**, 973–978 (2007).
- Wu, C. *et al.* Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. *Cancer Res.* **67**, 8216–8222 (2007).
- Wang, J. C. *et al.* High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. *Blood* **91**, 2406–2414 (1998).
- Al-Hajj, M. *et al.* Prospective identification of tumorigenic breast cancer cells. *Proc. Natl Acad. Sci. USA* **100**, 3983–3988 (2003).
- Cox, C. V. *et al.* Characterization of acute lymphoblastic leukemia progenitor cells. *Blood* **104**, 2919–2925 (2004).
- Hope, K. J., Jin, L. & Dick, J. E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. *Nature Immunol.* **5**, 738–743 (2004).
- Dalerba, P. *et al.* Phenotypic characterization of human colorectal cancer stem cells. *Proc. Natl Acad. Sci. USA* **104**, 10158–10163 (2007).
- O'Brien, C. A. *et al.* A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. *Nature* **445**, 106–110 (2007).
- Ricci-Vitiani, L. *et al.* Identification and expansion of human colon-cancer-initiating cells. *Nature* **445**, 111–115 (2007).
- Williams, R. T., den Besten, W. & Sherr, C. J. Cytokine-dependent imatinib resistance in mouse BCR-ABL⁺, *Arf*-null lymphoblastic leukemia. *Genes Dev.* **21**, 2283–2287 (2007).
- Kelly, P. N. *et al.* Tumor growth need not be driven by rare cancer stem cells. *Science* **317**, 337 (2007).
- Somervaille, T. C. & Cleary, M. L. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. *Cancer Cell* **10**, 257–268 (2006).
- Agliano, A. *et al.* Human acute leukemia cells injected in NOD/LtSz-SCID/IL- γ ^{null} mice generate a faster and more efficient disease compared to other NOD/SCID-related strains. *Int. J. Cancer* **123**, 2222–2227 (2008).
- Feuring-Buske, M. *et al.* Improved engraftment of human acute myeloid leukemia progenitor cells in β -2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors. *Leukemia* **17**, 760–763 (2003).
- Kennedy, J. A. *et al.* Comment on 'Tumor growth need not be driven by rare cancer stem cells'. *Science* **318**, 1722; author reply 1722 (2007).
- Pardal, R., Clarke, M. F. & Morrison, S. J. Applying the principles of stem-cell biology to cancer. *Nature Rev. Cancer* **3**, 895–902 (2003).
- Wang, J. C. & Dick, J. E. Cancer stem cells: lessons from leukemia. *Trends Cell Biol.* **15**, 494–501 (2005).
- Shackleton, M. *et al.* Generation of a functional mammary gland from a single stem cell. *Nature* **439**, 84–88 (2006).
- Shultz, L. D. *et al.* Human lymphoid and myeloid cell development in NOD/LtSz-scid *IL2R γ ^{null}* mice engrafted with mobilized human hemopoietic stem cells. *J. Immunol.* **174**, 6477–6489 (2005).
- Ito, M. *et al.* NOD/SCID/ γ _c^{null} mouse: an excellent recipient mouse model for engraftment of human cells. *Blood* **100**, 3175–3182 (2002).
- McKenzie, J. L. *et al.* Human short-term repopulating stem cells are efficiently detected following intrafemoral transplantation into NOD/SCID recipients depleted of CD122⁺ cells. *Blood* **106**, 1259–1261 (2005).
- Shultz, L. D. *et al.* Regulation of human short-term repopulating cell (STRC) engraftment in NOD/SCID mice by host CD122⁺ cells. *Exp. Hematol.* **31**, 551–558 (2003).

25. Hamada, K. *et al.* Liver metastasis models of colon cancer for evaluation of drug efficacy using NOD/Shi-scid IL2R γ^{null} (NOG) mice. *Int. J. Oncol.* **32**, 153–159 (2008).
26. Suemizu, H. *et al.* Identification of a key molecular regulator of liver metastasis in human pancreatic carcinoma using a novel quantitative model of metastasis in NOD/SCID/ γ^{null} (NOG) mice. *Int. J. Oncol.* **31**, 741–751 (2007).
27. Ishikawa, F. *et al.* Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. *Nature Biotechnol.* **25**, 1315–1321 (2007).
28. Kleinman, H. K. & Martin, G. R. Matrigel: basement membrane matrix with biological activity. *Semin. Cancer Biol.* **15**, 378–386 (2005).
29. Pretlow, T. G. *et al.* Transplantation of human prostatic carcinoma into nude mice in Matrigel. *Cancer Res.* **51**, 3814–3817 (1991).
30. Sweeney, T. M. *et al.* Basement membrane and the SIKVAV laminin-derived peptide promote tumor growth and metastases. *Cancer Metastasis Rev.* **10**, 245–254 (1991).
31. Fridman, R. *et al.* Enhanced tumor growth of both primary and established human and murine tumor cells in athymic mice after coinjection with Matrigel. *J. Natl Cancer Inst.* **83**, 769–774 (1991).
32. Singh, S. K. *et al.* Identification of human brain tumour initiating cells. *Nature* **432**, 396–401 (2004).
33. Iwashita, T. *et al.* Hirschsprung disease is linked to defects in neural crest stem cell function. *Science* **301**, 972–976 (2003).
34. Bao, S. *et al.* Targeting cancer stem cells through L1CAM suppresses glioma growth. *Cancer Res.* **68**, 6043–6048 (2008).
35. Frank, N. Y. *et al.* ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. *Cancer Res.* **65**, 4320–4333 (2005).
36. Yilmaz, O. H. *et al.* Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. *Nature* **441**, 475–482 (2006).
37. Horwich, A., Shipley, J. & Huddart, R. Testicular germ-cell cancer. *Lancet* **367**, 754–765 (2006).
38. Kleinman, L. J. & Pierce, G. B. Multipotentiality of single embryonal carcinoma cells. *Cancer Res.* **24**, 1544–1551 (1964).
39. Bonnefoix, T. *et al.* Fitting limiting dilution experiments with generalized linear models results in a test of the single-hit Poisson assumption. *J. Immunol. Methods* **194**, 113–119 (1996).
40. Nakajima, T. *et al.* Immunohistochemical demonstration of S100 protein in malignant melanoma and pigmented nevus, and its diagnostic application. *Cancer* **50**, 912–918 (1982).

Supplementary Information is linked to the online version of the paper at www.nature.com/nature.

Acknowledgements This work was supported by the Howard Hughes Medical Institute and by the Allen H. Blondy Research Fellowship. The University of Michigan Melanoma Bank was supported by a gift from Lewis and Lillian Becker. Flow cytometry was partly supported by the University of Michigan Comprehensive Cancer Center grant from the National Institutes of Health CA46592. We thank: D. Adams, M. White and the University of Michigan Flow Cytometry Core Facility for support; N. McAnsh and the University of Michigan Cancer Centre Histology Core for histological studies; G. K. Smyth for assistance with statistics; and Z. Azizan for support with tissue collection. Antibody production was supported in part by the National Institute of Diabetes, Digestive, and Kidney Diseases, grant NIH5P60-DK20572 to the Michigan Diabetes Research and Training Center. Some antibodies were provided by Caltag or by eBioscience to screen for cancer stem-cell markers. Human primary melanocyte cultures were provided by M. Soengas. Human mesenchymal stem cells were provided by Z. Wang and P. Krebsbach. E.Q. was supported by the Spanish Ministry of Education and the Marie Curie Outgoing International Fellowship from the European Commission. M.S. was supported by the Australian National Health and Medical Research Council, the Human Frontiers Science Program and Australia Post.

Author Contributions E.Q., M.S. and S.J.M. planned the project. E.Q. and M.S. performed the experiments, and analysed data with S.J.M. M.S.S. and T.M.J. obtained consent from the patients and surgically obtained many of the melanoma specimens. D.R.F. performed all pathology and diagnosed the tumours with T.M.J. T.M.J. banked the melanomas, and provided clinical information. E.Q., M.S. and S.J.M. wrote the paper.

Author Information Reprints and permissions information is available at www.nature.com/reprints. Correspondence and requests for materials should be addressed to S.J.M. (seanjm@umich.edu).

METHODS

Cell preparation. Tumours were mechanically dissociated with a McIlwain tissue chopper (Mickle Laboratory Engineering Co.) before sequential enzymatic digestion in 200 U ml⁻¹ collagenase IV (Worthington) for 20 min followed by 0.05% trypsin-EGTA for 5 min, both at 37 °C. DNase (50–100 U ml⁻¹) was added to reduce clumping of cells during digestion. Cells were filtered (40-µm cell strainer) to obtain a single-cell suspension. Dead cells and debris were reduced by density centrifugation (1.1 g ml⁻¹ Optiprep, Sigma) and/or magnetic bead separation (Dead Cell Removal Kit; Miltenyi Biotec) as necessary. Primary human melanocytes⁴¹ and mesenchymal stem cells⁴² were cultured as described.

Cell labelling and sorting. All antibody labelling of cells was performed for 20 min on ice, followed by washing and centrifugation. Secondary antibodies were conjugated to phycoerythrin (goat anti-mouse IgG or IgM, goat anti-rat IgG or goat anti-rabbit IgG; Jackson ImmunoResearch). Primary isotype controls followed by the same secondary antibodies were used to set background. Cells were subsequently stained with directly conjugated antibodies to human CD45 (HI30-APC, BD Biosciences), human CD31 (WM59-APC, eBiosciences) and Glycophorin A (HIR2-APC, Biolegend) (for tumours obtained directly from patients) or mouse CD45 (30-F11-APC, eBiosciences), mouse CD31 (390-APC, Biolegend), Ter119 (TER-119-APC, eBiosciences) and human HLA-A,B,C (G46-2.6-FITC, BD Biosciences) (for xenograft tumours) to select live human melanoma cells and to exclude endothelial and haematopoietic cells. Cells were re-suspended in 10 µg ml⁻¹ DAPI (Sigma) and sorted on a FACSVantage SE-dual laser, three line flow cytometer or a FACSaria Cell Sorter (Becton Dickinson). After sorting, an aliquot of sorted cells was always re-analysed to check for purity, which was usually greater than 95%. Magnetic cell separation using the CD133 Cell Isolation Kit (Miltenyi Biotec) was performed according to the manufacturer's instructions.

Identification of single melanoma cells. Sorted cells were diluted and aliquoted into 10-µl microwells (Thermo Fisher Scientific). Plates were centrifuged at 450g for 30 s and wells containing single cells were identified by phase-contrast microscopy. In control experiments, the presence of microscopically identified single cells was confirmed by Acridine Orange staining, which demonstrated a single nucleus in 90/90 cases. Cell doublets could be identified easily, were rare (7 of 312 wells examined) and were discarded. Wells containing single cells were transferred to a syringe containing Matrigel before injection. Cell transfer to the syringe was confirmed by observing the absence of a cell in the well it came from.

Transplantation of melanoma cells. Subcutaneous injections were performed into each flank and the interscapular region of each mouse. Tumour formation was evaluated regularly by palpation of injection sites, and tumour diameters were measured with callipers. Mice were monitored for up to 32 weeks after injection. In cases where a tumour became palpable at only one injection site and was causing the mouse distress, that tumour was surgically removed to allow continued evaluation of other injection sites. Tumours were only evident at injection sites and we never observed subcutaneous metastases. To confirm this,

we performed a single subcutaneous injection of 200 cells from tumour 205 into each of six NOD/SCID *Il2rg*^{-/-} mice after mixing in Matrigel and observed only one tumour per mouse at the injection site. The presence of human melanomas was always confirmed at necropsy based on gross examination and marker expression.

Histopathology and immunostaining. Portions of melanoma tumours used in experiments were fixed in 10% neutral buffered formalin, paraffin embedded, sectioned and stained with haematoxylin and eosin for histopathology analysis. Paraffin-embedded tumours were confirmed as melanomas by staining for S100 and HMB45 expression after quenching endogenous peroxidase activity. Binding of anti-S100 antibody (DAKO) was performed for 30 min at room temperature, detected by anti-rabbit secondary (30 min at room temperature) and revealed using DAB chromagen. Binding of HMB45 antibody (DAKO) was performed for 30 min at room temperature after antigen retrieval with proteinase K, detected using the M.O.M. immunodetection kit (Vector Laboratories) and revealed using DAB. S100- and HMB45-stained slides were counterstained with haematoxylin. For staining of sorted cells, cells from tumours were cytopun (18g for 6 min) onto slides after fixation with 4% paraformaldehyde for 5 min at room temperature. For immunofluorescence, slides were rinsed in PBS and blocked in goat serum solution (PBS containing 5% goat serum, 1% BSA and 0.3% Triton X-100) for 1 h to reduce non-specific antibody binding. Incubation with S-100β antibody (Sigma, diluted 1:200 in goat serum solution) was performed overnight at 4 °C, followed by secondary goat anti-mouse IgG1 Alexa 488 (Invitrogen) for 2 h at room temperature. Slides were counterstained with DAPI for 10 min at room temperature, then mounted in fluorescent mounting solution (DAKO). For detection of melanin pigment, the Fontana-Masson method was used⁴³. Slides were microwaved for 1 min in 2.5% Fontana silver nitrate solution (Sigma), before rinsing and toning with 0.2% gold chloride for 2 min. After rinsing, slides were incubated in 5% sodium thiosulphate (Sigma) for 2 min, washed and nuclei were stained with DAPI. Slides were mounted in DAKO fluorescent mounting solution.

Statistics. Differences between mean times to tumour palpability were compared using unpaired *t*-tests. Tumour growth rates were determined by calculating averaged linear regression slopes of the diameters of each tumour at each time point, monitored for at least 10 days and displayed with dot points representing the mean (±s.d.) of the diameters of all tumours palpable at the indicated time points.

41. Fernandez, Y. *et al.* Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. *Cancer Res.* 65, 6294–6304 (2005).
42. Wang, Z. *et al.* Ablation of proliferating marrow with 5-fluorouracil allows partial purification of mesenchymal stem cells. *Stem Cells* 24, 1573–1582 (2006).
43. Bancroft, J. D. & Stevens, A. *Theory and Practice of Histological Techniques* (Churchill Livingstone, 1990).

SUPPLEMENTARY TABLES

Supplementary table 1. Melanomas from 17 of 19 patients tested grew in immunocompromised mice and could almost always be serially passaged.

patient	age/ sex	AJCC clinical stage	tumor site	no. tumors propagated / no. tumors attempted									
				xenograft generation									
				1	2	3	4	5	6	7	8	9	
193	62/M	III	Lymph Node	1/1	3/3	1/1	2/2	3/3	2/2	3/3			
205	78/M	IV	Subcutaneous	1/1	2/2	4/4	5/5	4/4	4/4	6/6	3/3	1/1	
214	51/M	III	Lymph Node	1/1	5/5	5/5	1/1	1/1	2/2	1/1	4/4		
220	72/M	III	Lymph Node	0/1									
261	80/M	III	Subcutaneous	0/1									
308	76/F	III	Lymph Node	1/1	3/3	6/6	3/3	3/3	2/2				
320	41/M	III	Lymph Node	1/1	1/1	1/1	2/2						
326	43/M	III	Subcutaneous	1/1	1/1	0/1							
376	68/M	III	Lymph Node	1/1	1/1								
405	29/M	III	Lymph Node	1/1	2/2	1/1							
409	48/M	III	Lymph Node	1/1	1/1								
465	61/F	IV	Subcutaneous	1/1									
481	67/M	III	Cutaneous*	1/1	1/1	1/1							
487	54/M	IV	Cutaneous [§]	1/1	1/1								
491	41/F	III	Lymph Node	1/1	1/1								
492	40/M	III	Lymph Node	1/1	1/1								
498	83/M	III	Cutaneous [†]	1/1									
501	71/M	III	Lymph Node	1/1									
509	79/M	III	Cutaneous [†]	1/1									
TOTAL:				17/19	23/23	19/20	13/13	11/11	10/10	10/10	7/7	1/1	


7 of 9 tumors (patients 193 – 214 and 308 – 376) obtained directly from patients were successfully established in NOD/SCID mice. All of the 10 tumors obtained directly from patients that were initially injected into NOD/SCID IL2R γ ^{null} mice were successfully established (patients 405 – 509). These included 4 cutaneous melanomas: 1 locally recurrent lesion*, 1 cutaneous metastasis[§] and 2 primary cutaneous lesions[†] that presented with lymph node metastases. Only one tumor failed to retransplant (3rd generation of cells from patient 326 transplanted into NOD/SCID mice) out of 95 total attempts. We have therefore not detected significant numbers of tumors that could not be passaged. Moreover, the vast majority of tumors grew rapidly once palpable; we rarely observed tumors that remained small (<1cm) when the mice died. None of the patients had been treated other than with surgery, except for patient 465 who received adjuvant interferon.

Supplementary table 2: A number of markers are heterogeneously expressed by melanoma cells from multiple patients, but none of the markers tested so far in tumor formation assays clearly distinguishes tumorigenic from non-tumorigenic cells.

marker	clone	source	% marker +							in vivo test			
			patient							tested in vivo?	tumors formed		
			193	205	214	308	405	481	491		492	marker -/low	marker +
A2B5	A2B5-105	Chemicon	16%	96%	74%	23%	99%	95%	18%	94%	Y (n=7)	+	+
CD9	RPM.7	BDPharmingen	92%	98%	98%	-	-	84%	49%	82%	N		
CD20	2H7	eBiosciences	0%	0%	0%	0%	-	0%	0%	0%	N		
CD24	HIS50	BDPharmingen	1%	0%	2%	2%	8%	21%	0%	0%	N		
CD29	MEM-101A	eBiosciences	100%	100%	100%	66%	100%	83%	78%	92%	N		
CD44	515	BDPharmingen	70%	99%	100%	73%	100%	88%	61%	100%	Y (n=1)	+	+
CD49 b	12F1-H6	BDPharmingen	75%	73%	76%	76%	-	47%	63%	85%	Y (n=1)	+	+
CD49 d	9F10	eBiosciences	39%	72%	52%	61%	8%	0%	3%	78%	Y (n=4)	+	+
CD49 e	IIA1	BDPharmingen	97%	-	-	76%	36%	2%	2%	35%	N		
CD49 f	GoH3	BDPharmingen	98%	0%	0%	100%	-	89%	68%	93%	Y(n=2)	+	+
CD54	HA58	eBiosciences	67%	99%	99%	86%	100%	69%	80%	89%	Y (n=2)	+	+
CD63	H5C6	DSHB*	48%	94%	90%	80%	99%	87%	57%	79%	N		
CD133	AC133	MACS	0%	0%	2%	1%	3%	1%	5%	0%	Y(n=4)	+	+
CD150	A12(7D4)	eBiosciences	3%	0%	9%	-	-	-	-	-	N		
CD166	3A6	BDPharmingen	38%	68%	88%	77%	3%	60%	0%	24%	Y(n=5)	+	+
Ckit	YB5.B8	eBiosciences	0%	70%	2%	15%	8%	55%	0%	7%	Y (n=2)	+	+
Cmet	eBioclone97	eBiosciences	0%	-	-	0%	0%	0%	0%	0%	N		
Cripto	#89633	R&D Systems	2%	0%	6%	5%	-	5%	2%	3%	N		
E-Cadherin	HECD-1	Zyomed	0%	88%	76%	91%	3%	29%	0%	65%	Y (n=1)	+	+
HNK1	hybridoma	David	4%	99%	2%	99%	26%	20%	0%	0%	Y (n=5)	+	+
L1CAM	5G3	BDPharmingen	9%	29%	42%	94%	94%	12%	49%	61%	Y (n=4)	+	+
L6	D1-D2	Chemicon	7%	-	-	-	91%	-	-	-	N		
MCAM	P1H12	BDPharmingen	62%	25%	98%	99%	80%	67%	19%	100%	Y (n=2)	+	+
MDR1	MM4.17	Chemicon	0%	-	19%	0%	-	24%	0%	0%	N		
MMA	hybridoma	DSHB*	0%	0%	0%	0%	-	-	-	-	N		
NCAM	SP2/0	DSHB*	-	-	-	-	0%	0%	0%	0%	N		
N-Cadherin	GC4	Sigma	0%	-	4%	3.7%	3%	1.7%	0%	0%	Y (n=1)	+	+
NrCAM	polyclonal	abCAM	1%	-	-	-	33%	23%	1%	2%	N		
O4	hybridoma	David	32%	0%	0%	-	-	90%	0%	18%	N		
p75	NGFR5	Biosource	58%	3%	60%	3%	10%	2%	7%	23%	Y (n=10)	+	+
SSSEA-4	SP2/0	DSHB*	-	-	0%	-	-	0%	0%	0%	N		
stro-1	NS1-Ag4-1	DSHB*	0%	0%	15%	-	-	-	-	-	N		
VE-	16B1	eBiosciences	-	0%	0%	-	-	0%	0%	1%	N		
CD2	S5.5	Caltag	0%	-	0%	-	-	-	-	-	N		
CD4	S3.5	Caltag	0%	-	0%	-	-	-	-	-	N		
CD7	CD7-6B7	Caltag	0%	-	0%	-	-	-	-	-	N		
CD8	3B5	Caltag	0%	-	0%	-	-	-	-	-	N		
CD13	TUK 1	Caltag	25%	0%	0%	-	-	-	-	-	N		
CD14	biG 53	Caltag	1%	-	-	-	-	-	-	-	N		
CD26	2A6	eBiosciences	6%	94%	0%	-	-	0%	0%	70%	N		
CD30	HRS-4	Caltag	6%	-	0%	-	-	-	-	-	N		
CD33	WM53	BDPharmingen	-	-	4%	-	-	-	-	-	N		
CD50	TP1/25.1	Caltag	0%	-	-	-	-	-	-	-	N		
CD52	CF1D12	Caltag	0%	-	0%	-	-	-	-	-	N		
CD73	AD2	BDPharmingen	6%	-	-	-	-	-	-	-	N		
CD90	5E10	BDPharmingen	6%	-	-	-	-	-	-	-	N		
CD105	43A3	Biolegend	2%	-	-	-	-	-	-	-	N		
CD140a	alphaR1	BDPharmingen	40%	-	0%	-	-	-	-	-	N		
CD147	8D12	eBiosciences	-	94%	100%	-	-	77%	62%	100%	N		
GD2	P3x63 Ag8.653	DSHB*	-	-	-	-	0%	0%	0%	0%	N		

DSHB*: Developmental Studies Hybridoma Bank

SUPPLEMENTARY FIGURES AND LEGENDS




Supplementary Figure 1. Melanomas became palpable earlier and grew faster in NOD/SCID IL2R γ ^{null} mice as compared to NOD/SCID mice. Upper panels show that the times to first palpability for tumors derived from cells isolated from 5 separate xenografted melanomas were significantly longer (*p < 0.05, Student's t-test) in NOD/SCID mice (blue) as compared to NOD/SCID IL2R γ ^{null} mice (red). Dots indicate


individual tumors and lines indicate means. Lower panels show the average linear regression slopes for the diameter of each tumor monitored for at least 10 days (mean \pm s.d. is shown for time points at which multiple tumors were available to evaluate). Tumor size thus usually increased more quickly in NOD/SCID IL2R γ^{null} mice (red) as compared to NOD/SCID mice (blue) after tumors became palpable. Each panel shows data from the lowest cell dose that formed tumors in both mouse strains.

tumor origin	patient	mouse strain	no. tumors / no. injections							melanoma-initiating cell frequency (95%CI)				
			cells/injection (x1,000)											
			30	20	15	10	6	4	2	1	0.5			
xenografts	214	NOD/SCID	2/6	0/6			0/6		0/6				1/148,000 (1/37,500 - 1/585,000)	
		NOD/SCID IL2R γ^{null}	6/6	6/6			6/6		1/6				1/1,400* (1/560 - 1/3,400)	
	205	NOD/SCID	7/9				0/6	0/6					1/29,655 (1/14,200 - 1/61,800)	
		NOD/SCID IL2R γ^{null}	5/5	5/5			6/6	5/6					1/998* (1/434 - 1/2,300)	
	308	NOD/SCID	6/6	1/6			3/5	0/6					1/17,000 (1/8,900 - 1/33,000)	
		NOD/SCID IL2R γ^{null}	6/6	6/6			6/6	1/6					1/2,800* (1/1,400 - 1/5,700)	
	193	NOD/SCID	8/12				5/6			0/6			1/11,900 (1/6,400 - 1/22,400)	
		NOD/SCID IL2R γ^{null}	8/9				6/6		7/12				1/2,000* (1/890 - 1/4,600)	
	405	NOD/SCID	2/6						1/6				1/28,000 (1/9,000 - 1/90,500)	
		NOD/SCID IL2R γ^{null}	6/6						3/3				(>1/1,600*)	
	direct from patients	465	NOD/SCID	0/6		0/6					0/3			(<1/81,000)
			NOD/SCID IL2R γ^{null}			2/6					0/6			1/28,000* (1/7,000 - 1/110,000)
481		NOD/SCID	0/3		4/6					0/6			1/33,750 (1/11,600 - 1/985,000)	
		NOD/SCID IL2R γ^{null}	6/6		6/6					6/6			(>1/662*)	

Supplementary Figure 2. Many more melanoma cells were tumorigenic in NOD/SCID IL2R γ^{null} mice as compared to NOD/SCID mice. Limiting dilution analyses of tumors that arose in NOD/SCID or NOD/SCID IL2R γ^{null} mice from the side-by-side transplantation of human melanoma cells obtained from either xenografted melanomas or directly from patients. Tumor formation was monitored for 32 weeks after transplantation. Melanoma cells obtained from xenografted tumors were isolated by flow-cytometry as in Fig. 2a. Melanoma cells obtained directly from patients were similarly isolated by flow-cytometry, except that human instead of mouse hematopoietic (CD45 and glycophorin A) and endothelial (CD31) cells were excluded. In all cases, the detectable frequency of melanoma-initiating cells was significantly (*p<0.05) higher in NOD/SCID IL2R γ^{null} mice. CI: confidence interval.




Supplementary Figure 3: The increased tumorigenicity of melanoma cells in NOD/SCID IL2R γ ^{null} mice as compared to NOD/SCID mice was determined by a more permissive environment for tumor formation rather than by heritable changes in the tumor as a result of growth in NOD/SCID IL2R γ ^{null} mice. When melanoma cells derived from a xenografted tumor that arose in NOD/SCID mice were injected side-by-side into NOD/SCID and NOD/SCID IL2R γ ^{null} mice, the frequency of tumorigenic cells was higher in NOD/SCID IL2R γ ^{null} mice. To test whether this represented an effect of the environment in these mice or a heritable change within the tumor itself (selection for more tumorigenic cells), cells derived from one of the tumors that grew in a NOD/SCID IL2R γ ^{null} mouse were retransplanted side-by-side into NOD/SCID and NOD/SCID IL2R γ ^{null} mice. The cells continued to form fewer tumors in NOD/SCID mice. This demonstrates that more melanoma cells are tumorigenic in NOD/SCID IL2R γ ^{null} mice, irrespective of whether the cells are derived from tumors grown in NOD/SCID mice, NOD/SCID IL2R γ ^{null} mice, or even derived directly from patients. Tumor formation was monitored for 32 weeks after transplantation in all experiments.




Supplementary Figure 4. Transplantation of melanoma cells mixed with Matrigel revealed a higher frequency of tumorigenic cells, and tumors that became palpable earlier and grew faster. a, Melanoma cells mixed with Matrigel (red) generally formed tumors faster (upper panels, dots indicate individual tumors and lines indicate means, * $p < 0.05$) than melanoma cells injected without Matrigel (black) in

NOD/SCID IL2R γ^{null} mice. These tumors also tended to grow faster once they became palpable (lower panels). Each panel shows data from the lowest cell dose that formed tumors under both conditions. **b**, Limiting dilution analyses of tumors that arose in NOD/SCID IL2R γ^{null} mice (up to 26 weeks after transplantation) from melanoma cells that were derived from xenografts, isolated by flow-cytometry and injected with either vehicle alone (black) or vehicle plus Matrigel (red). Vehicle is the staining medium described in the Methods. In all cases, the detectable frequency of melanoma-initiating cells was significantly (* $p < 0.05$) higher when melanoma cells were injected with Matrigel. As all injections with Matrigel developed tumors, we were only able to determine the lower 95% confidence limit of melanoma-initiating cell frequency for each tumor studied, rather than the limit dilution dose. CI: confidence interval. **c**, The frequency of tumorigenic melanoma cells in samples from 6 patients did not increase with passaging in NOD/SCID IL2R γ^{null} mice. The data in this table represent the tumors from which independent limit dilution analyses were performed in multiple generations of tumors using Matrigel and NOD/SCID IL2R γ^{null} mice. Generation P represents the frequency of tumorigenic cells among cells removed directly from patient tumors while each successive generation represents analyses of xenografted tumors.



Supplementary figure 5. CD49f and L1CAM do not distinguish tumorigenic from non-tumorigenic melanoma cells. Typical flow cytometric analyses of unfractionated melanoma cells from patients 491 (a) and 308 (c) stained with isotype control antibody and anti-CD49f (a) or anti-L1CAM (c) antibodies. Plots show live human melanoma

cells as in Fig. 2a. CD49⁻ and CD49⁺ cells (**b**) and L1CAM⁻ and L1CAM⁺ cells (**d**) isolated by flow cytometry from xenografted tumors were injected into NOD/SCID IL2R γ ^{null} mice with Matrigel and monitored for up to 26 weeks. The data are from two independent experiments per marker. The frequency of tumorigenic cells in each fraction was calculated by limiting dilution analysis. All fractions exhibited a high frequency of tumorigenic cells, irrespective of marker expression. The various fractions of cells also did not significantly differ in terms of the time required for the formation of palpable tumors from the injection of 5 or 10 cells (CD49⁻=8±2, CD49⁺=10±2 weeks, L1CAM⁻= 9±1, L1CAM⁺=8±1 weeks; mean±s.d.).



Supplementary figure 6. CD133 and CD166 do not distinguish tumorigenic from non-tumorigenic melanoma cells. **a**, and **d**, Typical flow cytometric analyses of unfractionated melanoma cells from patient 308 (**a**) and 193 (**d**) stained with isotype control antibody and anti-CD133 (**a**) or anti-CD166 (**d**) antibodies. Plots show live

human melanoma cells as in Fig. 2a. Summary of CD133 (**b**) and CD166 (**e**) expression in unfractionated cells from melanomas derived from 12 patients, as evaluated by flow cytometry. ND means not determined. The frequency of CD133⁺ cells was almost always lower than the frequency of tumorigenic cells, indicating that CD133 could not distinguish tumorigenic from non-tumorigenic cells. Cells from xenografted tumors isolated based on CD133 (**c**) or CD166 (**f**) expression were transplanted into NOD/SCID IL2R γ^{null} mice after mixing with Matrigel and monitored for up to 26 weeks. The frequency of tumorigenic cells in each fraction was calculated by limiting dilution analysis. All fractions exhibited a high frequency of tumorigenic cells, irrespective of marker expression. The various fractions of cells also did not significantly differ in terms of the time required for the formation of palpable tumors from the injection of 10 cells (CD133⁻=11 \pm 2, CD133⁺=9 \pm 2 weeks, CD166⁻= 11 \pm 2, CD166⁺=8 \pm 5 weeks; mean \pm s.d.).